MedAssets reiterates guidance for FY12 adjusted EPS $1.10 at midpoint Consensus $1.12. Reiterates view of FY12 revenue $635.0M at midpoint, consensus $636.2M. Says consolidated net revenue guidance increased by about 1.5% following its Q3 report based on nine]month 2012 performance and visibility through remainder of year. Says YTD 2012 results ahead of its expectations. Guidance and comments from presentation slides for J.P. Morgan Healthcare Conference.
News For MDAS From The Last 14 Days
Check below for free stories on MDAS the last two weeks.
MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.
MedAssets pullback a buying opportunity, says Jefferies Jefferies believes MedAssets' core business is back on track following yesterday's analyst day and it recommends buying the stock on the recent pullback. The firm has a Buy rating on the name with a $30 price target.